3 Healthcare Stocks Paying the Highest Dividends of 2025

The article evaluates three high-yield healthcare stocks for institutional investors: Kenvue, Pfizer, and Omega Healthcare. Kenvue, recently spun off from Johnson & Johnson, offers a 5.5% yield but faces initial sales declines and product-specific risks, though its consumer staples nature suggests underlying stability. Pfizer, with a 6.9% yield, is navigating a patent cliff and industry headwinds with strategic acquisitions, but its high 90% payout ratio and history of dividend cuts present a significant risk to its current dividend. Conversely, Omega Healthcare, a senior housing REIT yielding 6.6%, is highlighted as the most reliable, having maintained its dividend through the pandemic and now resuming growth, making it a more stable income play.

Analysis

Kenvue, recently spun off from Johnson & Johnson, is experiencing initial operational challenges, with Q2 2025 sales declining 4% and organic sales down 4.2%, alongside a drop in adjusted earnings from $0.32 to $0.29 per share. The stock has faced pressure, partly due to concerns regarding Tylenol's potential pregnancy risks, leading to its current 5.5% dividend yield, significantly above the consumer staples average of 2.7%. Despite these headwinds, its consumer staples nature suggests underlying stability, though it lacks a dividend track record.

Pfizer, while a seasoned pharmaceutical company, is navigating significant industry headwinds and a patent cliff, reflected in its stock's nearly 60% decline since late 2021. The company is strategically responding with a U.S. government deal and the acquisition of Metsera to bolster its pipeline. However, its high 6.9% dividend yield is accompanied by a precarious 90% payout ratio and a history of dividend cuts, notably in 2009, posing a material risk to its current payout.

In contrast, Omega Healthcare, a senior-housing REIT, presents a more stable income profile with a 6.6% dividend yield. The company demonstrated exceptional resilience by maintaining its dividend throughout the challenging COVID-19 pandemic, a period when many peers resorted to cuts. With the pandemic's impact largely subsiding and over $0.5 billion in assets acquired in Q2 2025, Omega Healthcare is positioned for renewed growth and more normalized operations.

Key Decisions for Investors

• Investors should approach Kenvue with caution, balancing its high 5.5% yield and consumer staples stability against recent operational declines and the lack of a long-term dividend track record.
• Pfizer's 6.9% dividend yield carries significant risk due to its 90% payout ratio and history of cuts, suggesting investors should prioritize the company's turnaround potential over dividend reliability.
• Omega Healthcare stands out as a more stable income option with a 6.6% yield, having demonstrated strong dividend resilience through the pandemic and now resuming growth, making it a potentially attractive choice for income-focused portfolios.